| Title |
Targeting CD30 in Anaplastic Large Cell Lymphoma
|
|---|---|
| Published in |
Current Hematologic Malignancy Reports, October 2012
|
| DOI | 10.1007/s11899-012-0137-y |
| Pubmed ID | |
| Authors |
Joseph Vadakara, Barbara Pro |
| Abstract |
Anaplastic large cell lymphoma (ALCL) is a lymphoid neoplasm characterized by strong and uniform expression of the CD30 antigen on the cell surface. Current standard frontline therapy of ALCL is anthracycline-based combination chemotherapy, usually CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOP-like regimens. Despite aggressive chemotherapy a significant number of patients relapse. Newer agents and strategies are needed in the management of this challenging disease especially in ALK-negative and high-risk ALK-positive patients who tend to have a poor prognosis. In this review we discuss the different approaches to targeting CD30 including naked antibodies, "enhanced antibodies", antibody drug-toxin conjugates, radioimmunoconjugates, CD30-ligand-toxin conjugates, bispecific antibodies and T cell-based immune therapies. |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 13 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 3 | 23% |
| Student > Ph. D. Student | 3 | 23% |
| Other | 2 | 15% |
| Student > Postgraduate | 2 | 15% |
| Researcher | 1 | 8% |
| Other | 1 | 8% |
| Unknown | 1 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 54% |
| Agricultural and Biological Sciences | 3 | 23% |
| Immunology and Microbiology | 1 | 8% |
| Biochemistry, Genetics and Molecular Biology | 1 | 8% |
| Unknown | 1 | 8% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 February 2013.
All research outputs
#20,192,189
of 22,709,015 outputs
Outputs from Current Hematologic Malignancy Reports
#372
of 427 outputs
Outputs of similar age
#154,405
of 173,765 outputs
Outputs of similar age from Current Hematologic Malignancy Reports
#6
of 6 outputs
Altmetric has tracked 22,709,015 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 427 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 173,765 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.